.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Cantor Fitzgerald
US Department of Justice
Julphar
Chinese Patent Office
Accenture
UBS
Novartis
Fuji
Baxter

Generated: July 20, 2017

DrugPatentWatch Database Preview

Alogliptin benzoate; pioglitazone hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for alogliptin benzoate; pioglitazone hydrochloride and what is the scope of alogliptin benzoate; pioglitazone hydrochloride freedom to operate?

Alogliptin benzoate; pioglitazone hydrochloride
is the generic ingredient in one branded drug marketed by Takeda Pharms Usa and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Alogliptin benzoate; pioglitazone hydrochloride has two hundred and thirty-one patent family members in forty-four countries.

There are nine drug master file entries for alogliptin benzoate; pioglitazone hydrochloride. Two suppliers are listed for this compound.

Summary for Generic Name: alogliptin benzoate; pioglitazone hydrochloride

Tradenames:1
Patents:11
Applicants:1
NDAs:1
Drug Master File Entries: see list9
Suppliers / Packagers: see list2
Clinical Trials: see list2,671
Drug Prices:see low prices
DailyMed Link:alogliptin benzoate; pioglitazone hydrochloride at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-004Jan 25, 2013RXYesNo8,173,663► Subscribe ► Subscribe
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-002Jan 25, 2013RXYesNo8,288,539► SubscribeY ► Subscribe
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-002Jan 25, 2013RXYesNo6,303,661► Subscribe ► Subscribe
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-002Jan 25, 2013RXYesNo► Subscribe► Subscribe
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-005Jan 25, 2013RXYesNo6,303,640► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: alogliptin benzoate; pioglitazone hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-002Jan 25, 20135,965,584► Subscribe
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-003Jan 25, 20136,271,243► Subscribe
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-005Jan 25, 20136,303,640► Subscribe
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-002Jan 25, 20136,166,043► Subscribe
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-004Jan 25, 20136,166,043► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: alogliptin benzoate; pioglitazone hydrochloride

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,829,530Method of regulating glucose metabolism, and reagents related thereto► Subscribe
6,133,293 Pharmaceutical composition► Subscribe
6,288,090 Pharmaceutical composition► Subscribe
6,169,100 Pharmaceutical composition► Subscribe
6,232,330 Pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: alogliptin benzoate; pioglitazone hydrochloride

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2008093882► Subscribe
Argentina091289► Subscribe
CroatiaP20080509► Subscribe
Hong Kong1010484► Subscribe
Eurasian Patent Organization015180► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0006France► SubscribePRODUCT NAME: PIOGLITAZONE/METFORMINE ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/06/354/001 DU 20060728; REGISTRATION NO/DATE AT EEC: EU/1/06/354/001 DU 20060728
1084705/05Switzerland► SubscribePRODUCT NAME: ALOGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 62955 21.11.2013
C/GB14/086United Kingdom► SubscribePRODUCT NAME: VILDAGLIPTIN; REGISTERED: UK EU/1/07/414/001-017 20070928
2014 00064Denmark► SubscribePRODUCT NAME: VILDAGLIPTIN; REG. NO/DATE: EU/1/07/414/001-017 20070928
0280Netherlands► Subscribe300280, 20170424, EXPIRES: 20220320
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Express Scripts
McKesson
Boehringer Ingelheim
Chubb
Novartis
Merck
Daiichi Sankyo
UBS
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot